Bio-Techne (TECH) reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago figure of 48 cents.The quarter's adjustments eliminated the impact of certain one-time items, including amortization of intangibles and Wilson Wolf intangible assets, acquired inventory, and restructuring and restructuring-related costs, among others.GAAP EPS was 14 cents compared with 31 cents in the prior-year q ...

Elanco Animal Health Incorporated  ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That’s up 9% year over year.The company beat the management guidance of 29 to 34 cents and the consensus of 31 cents.Elanco reported sales of $1.19 billion. It beat the consensus of $1.17 billion and the management guidance of $1.16 billion-$1.18 billion.Sales decreased 1% on a reported basis and increased 4% on organic constant currency growth.Also Read: Elanco Animal Health Sells Xdemvy Royalties T ...

Financial Performance - For the quarter ended March 2025, Teradata reported revenue of $418 million, down 10.1% year-over-year, and EPS of $0.66, compared to $0.57 in the same quarter last year [1] - The reported revenue was below the Zacks Consensus Estimate of $425.28 million, resulting in a surprise of -1.71%, while the EPS exceeded the consensus estimate of $0.57 by +15.79% [1] Key Metrics - Annual recurring revenue (ARR) totaled $1.44 billion, matching the average estimate from two analysts [4] - Public Cloud ARR was reported at $606 million, surpassing the average estimate of $590.05 million [4] - Revenue from perpetual software licenses and hardware was $10 million, significantly above the estimated $4.85 million, reflecting a +25% change year-over-year [4] - Recurring revenue was $358 million, below the average estimate of $368.40 million, indicating a -7.7% change year-over-year [4] - Consulting services revenue was $50 million, slightly below the average estimate of $52.03 million, with a gross profit of -$3 million compared to an estimated $4.64 million [4] - Gross profit from recurring revenue was $250 million, slightly below the estimated $256.11 million [4] Stock Performance - Teradata shares have returned +15.1% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

JPMorgan analyst Christopher Horvers lowered estimates for Lowe’s Companies Inc. LOW ahead of the company’s first-quarter earnings release on May 21.The analyst says that based on the industry analysis and data insights, he is cutting first-quarter comparable sales estimates to -2.7%, below the Street’s consensus of -1.7% and the broader buyside expectations (a decline of 2% to 3.5%).Horvers writes that Lowe’s experienced a more significant headwind from unfavorable DIY weather conditions earlier in the qua ...

Financial Data and Key Metrics Changes - In Q1 2025, comparable diluted earnings per share increased to $0.76 from $0.68 in Q1 2024, representing a 12% growth [12] - Comparable net earnings for Q1 2025 were $216 million, driven by higher volumes, lower interest expenses, and cost management initiatives [12][14] - The company anticipates a net debt to comparable EBITDA ratio of 2.75 times by year-end 2025 and plans to repurchase at least $1.3 billion worth of shares in 2025 [15][16] Business Line Data and Key Metrics Changes - North and Central America saw a 2% increase in comparable operating earnings, driven by stronger-than-expected volume performance, particularly in energy drinks and non-alcoholic beverages [12][13] - EMEA segment volume remained robust, with comparable operating earnings increasing by 13% [13] - South America experienced a 25% increase in segment comparable operating earnings, supported by strong volume performance across all markets [14] Market Data and Key Metrics Changes - Global shipments increased by 2.6% year-over-year in Q1 2025, with volume growth expected to be in the 2% to 3% range for the year [8][9] - In EMEA, mid-single-digit volume growth is anticipated for 2025, driven by the competitive advantages of aluminum packaging [9] - In South America, recovery in Argentina and Chile, along with growth in Brazil, is expected to drive volume growth above the long-term range of 4% to 6% in 2025 [9] Company Strategy and Development Direction - The company is focused on achieving 11% to 14% comparable diluted earnings per share growth in 2025 and generating record adjusted free cash flow [7][19] - A strategic partnership, Oasis Venture Holdings, was formed to enhance the aluminum cup business, indicating a focus on long-term growth potential [10] - The company emphasizes operational excellence, disciplined cost management, and driving efficiency across the organization [17][20] Management's Comments on Operating Environment and Future Outlook - Management remains confident in navigating uncertainties related to tariffs and consumer pressures, particularly in the U.S., while sustaining positive momentum [7][19] - The company is optimistic about the resilience of its global portfolio and strong customer alignment, which positions it well to handle potential economic slowdowns [10][19] - Management highlighted the importance of monitoring geopolitical developments and their potential impact on operations [17] Other Important Information - The company has repurchased $651 million worth of shares year-to-date and plans to continue aggressive stock repurchases [15] - The effective tax rate for 2025 is expected to be slightly above 22%, influenced by lower year-over-year tax credits [16] - Capital expenditures for 2025 are expected to be slightly below depreciation and amortization, in the range of $600 million [15][16] Q&A Session Summary Question: Can you frame your supply position in Europe and the next leg of incremental growth? - Management indicated that they have made significant investments in Europe, which allows for scaling up production, and they expect continued growth into 2026 and 2027 [25][28] Question: How are self-improvement initiatives tracking in North America? - Management noted that while they do not expect margin expansion, they are seeing improvements in Europe and South America due to lean initiatives [30] Question: What is the impact of tariffs on demand, particularly regarding Mexico beer exposure? - Management stated that the impact of tariffs is minimal and they have not seen significant changes in customer behavior or forecasts [36][38] Question: How is the promotional environment shaping up in major markets? - Management observed that there has been innovation in the energy segment and a more deliberate effort to price products to drive volume [46] Question: Can the company achieve 11% EPS growth if volume falls short due to tariffs? - Management expressed confidence in navigating uncertainties and highlighted the resilience of aluminum packaging in a recession [70][74] Question: What are the expectations for margin sustainability in North America? - Management acknowledged that maintaining current margins will be challenging due to affordability concerns among CPG customers [112][114] Question: How is the company adjusting its mix in specialty cans? - Management noted that there is growth in 12-ounce cans and that affordability is a key factor in the current market [115] Question: What are the trends in Latin America and expectations for growth? - Management indicated that Brazil is expected to see 2% to 3% growth, with recovery in Argentina and Chile contributing to overall growth in the region [121][123] Question: How should the market view supply-demand dynamics in Europe? - Management highlighted that Europe presents more growth opportunities than North America due to the shift away from glass packaging [125][128]

Group 1 - The individual is pursuing an MBA and draws inspiration from renowned investors such as Warren Buffett, Peter Lynch, and Terry Smith, focusing on quality companies at reasonable valuations [1] - The belief is that long-term fundamentals drive share prices, with a focus on predicting a business's earnings per share [1]

Core Viewpoint - Starbucks is facing challenges with its fiscal second-quarter earnings, which fell short of expectations, leading to a decline in share prices despite some progress in same-store sales improvement [1][4]. Financial Performance - Starbucks' adjusted earnings per share (EPS) dropped 40% year over year to $0.41, missing the analyst consensus of $0.49 [4]. - Overall revenue increased by 2% to $8.72 billion, falling short of the expected $8.82 billion [7]. Operational Changes - The new CEO, Brian Niccol, is prioritizing investment in human labor over equipment to enhance efficiency and customer experience, resulting in a 12% year-over-year increase in store operating expenses, which now account for 47.7% of revenue [2][3]. - The company's operating margin contracted by 450 basis points to 8.2%, attributed to the increased labor costs [3]. Sales Performance - Same-store sales decreased by 1%, marking an improvement compared to previous quarters, with global traffic down 2% but a 1% increase in average ticket [5]. - In North America, comparable-store sales fell by 1% with traffic down 4%, while international same-store sales rose by 2% with a 3% increase in traffic [6]. Strategic Focus - Starbucks is committed to menu innovation and product launches, such as the Cortado platform and summer berry refreshers, while managing tariffs through localization and sourcing strategies [8]. - The company aims to improve its brand image and customer retention through these strategic moves, despite the short-term pressure on profitability [10][12]. Valuation Insights - The stock has a forward price-to-earnings (P/E) ratio of approximately 27.5 based on fiscal 2025 estimates, indicating it is at one of the most attractive valuations since Niccol took over [11].

American International Group, Inc. (AIG) reported first-quarter 2025 adjusted earnings per share of $1.17, which beat the Zacks Consensus Estimate by 11.4%. However, the bottom line declined from the year-ago quarter’s $1.25. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Adjusted operating revenues amounted to $6.6 billion, which declined significantly year over year. Also, the top line missed the consensus mark by 2.6%.The better-than-expected first-quarter earnings were supported b ...

Core Insights - Tandem Diabetes Care, Inc. reported a first-quarter 2025 loss of 67 cents per share, which was worse than the previous year's loss of 63 cents and missed the Zacks Consensus Estimate of a loss of 60 cents per share [1] - Despite the earnings miss, TNDM's stock surged 18.6% following the announcement [1] - The company achieved record quarterly revenues, with non-GAAP revenues of $234.4 million, reflecting a year-over-year increase of 21.6% and surpassing the Zacks Consensus Estimate by 6.4% [2] Revenue Performance - Non-GAAP revenues for the first quarter were $234.4 million, up 21.6% year over year, and GAAP revenues also totaled $234.4 million, marking a 22.2% increase [2] - In the United States, non-GAAP sales reached $150.6 million, a 15% increase year over year, with over 17,000 pumps shipped [4] - Internationally, non-GAAP sales were $83.8 million, up from $61.9 million in the prior-year period [5] Margins and Expenses - Gross profit for the quarter was $118.4 million, a 25.1% increase year over year, with a gross margin of 50.5%, up 112 basis points despite a 19.6% rise in the cost of sales [6] - Selling, General and Administrative (SG&A) expenses rose 26.3% to $113.8 million, while Research and Development (R&D) expenses increased 8.6% to $50.2 million [6] - The adjusted operating loss was $45.7 million, compared to a loss of $41.7 million in the same period last year [6] Financial Position - At the end of the first quarter of 2025, Tandem Diabetes had cash, cash equivalents, and short-term investments totaling $368.6 million, down from $438.3 million at the end of the fourth quarter of 2024 [7] Guidance - The company reaffirmed its full-year 2025 GAAP financial guidance, estimating sales between $970 million and $1.007 billion, with the Zacks Consensus Estimate for full-year revenues at $1.00 billion [8] - GAAP sales in the United States are projected to be between $725 million and $730 million, while sales outside the United States are expected to be in the range of $272 million to $277 million [10] Overall Assessment - Tandem Diabetes ended the first quarter of 2025 with mixed results, as earnings lagged estimates but revenues exceeded expectations, driven by an expanding product portfolio [11] - The launch of Control-IQ+ technology for type 2 diabetes patients in the U.S. contributed to the strong performance [11] - However, the company's operating loss remains a concern [12]

Core Insights - Bio-Rad Laboratories, Inc. reported first-quarter 2025 adjusted EPS of $2.54, exceeding the Zacks Consensus Estimate of $1.73 by 46.8% and reflecting a 10.9% increase year-over-year [1][2] - The company experienced a revenue decline of 4.2% year-over-year, with Q1 revenues of $585.4 million missing the Zacks Consensus Estimate by 0.05% [3][10] - Bio-Rad lowered its financial guidance for full-year 2025, now expecting non-GAAP currency-neutral revenues to range from a 1.0% decline to 1.5% growth [7][9] Financial Performance - The GAAP EPS was reported at $2.29, a significant decrease from $13.45 a year ago [2] - Gross profit declined by 6.1% to $306 million, with gross margin contracting by 108 basis points to 52.3% [5] - Operating profit fell 46.9% to $23.7 million, with operating margin contracting by 325 basis points to 4% [5][11] Segment Analysis - Life Science segment sales totaled $228.6 million, down 5.4% year-over-year, primarily due to challenges in the academic research market [3][11] - Clinical Diagnostics segment net sales were $356.8 million, down 3.2% year-over-year, attributed to reduced reimbursements for diabetes testing in China [4][11] Cash Flow and Debt - Bio-Rad ended Q1 2025 with cash and cash equivalents of $1.66 billion, remaining flat sequentially [6] - Total debt at the end of 2024 was $1.20 billion, also flat on a sequential basis [6] - Net cash flow from operating activities increased to $129.9 million compared to $69.8 million a year ago [6] Market Reaction - Following the earnings announcement, Bio-Rad's stock rose by 0.2% in after-market trading [2]